在其他近期新闻中，Theravance Biopharma报告了2024年第三季度的积极业绩。公司的呼吸系统药物YUPELRI销售额显著增长，达到62.2百万美元，同比增长7%。医院对YUPELRI的需求也激增14%，剂量比去年同期增加40%。此外，公司的合作收入增至16.9百万美元，同比增长8%。

Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).

Theravance Biopharma Inc . (NASDAQ:TBPH) stock reached a 52-week high this week, touching $10.47 amid a fluctuating market. The company's shares have shown remarkable momentum with a 12.7% gain over ...

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest ...

This compares to the stock's 1.9% loss over the past four weeks. The company has developed Yupelri, a nebulized treatment for chronic obstructive pulmonary disease, in collaboration with Viatris.

Rhonda Farnum, Senior Vice President of Communications and Medical (TASE:PMCN) Affairs at Theravance Biopharma Inc . (NASDAQ:TBPH), recently sold a portion of her shares in the company. The stock has ...